BridgeBio Pharma, Inc. Increase (Decrease) in Other Operating Liabilities
BridgeBio Pharma, Inc. (BBIO) reported Increase (Decrease) in Other Operating Liabilities of $52.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-10
- BridgeBio Pharma, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was $47.79M, a 101.94% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $4.62M, a 56.77% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was $24.78M, a 129.42% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $26.42M.
- BridgeBio Pharma, Inc. increase (decrease) in other operating liabilities for fiscal 2025 was $77.81M, a 1757.48% increase from fiscal 2024.
- BridgeBio Pharma, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was $4.19M, a 19.11% increase from fiscal 2023.
- BridgeBio Pharma, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was $3.52M.
- BridgeBio Pharma, Inc. increase (decrease) in other operating liabilities for fiscal 2019 was -$65.00K, a 135.71% decline from fiscal 2018.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $52.41M 10-Q · filed 2026-08-10 | $77.19M derived: sum of 3 quarters · filed 2026-08-10 | $103.61M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $4.62M 10-Q · filed 2026-05-07 | $29.40M derived: sum of 2 quarters · filed 2026-05-07 | $55.82M derived: sum of 3 quarters · filed 2026-05-07 | $79.48M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $24.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $51.20M derived: sum of 2 quarters · filed 2026-02-24 | $74.86M derived: sum of 3 quarters · filed 2026-08-10 | $77.81M 10-K · filed 2026-02-24 |
| 2025-09-30 | $26.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $50.09M derived: sum of 2 quarters · filed 2026-08-10 | $53.03M 10-Q · filed 2025-10-29 | $63.83M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $23.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $26.61M 10-Q · filed 2026-08-10 | $37.41M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-03-31 | $2.94M 10-Q · filed 2026-05-07 | $13.75M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.19M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | -$6.61M 10-Q · filed 2025-10-29 | |||
| 2023-12-31 | $3.52M 10-K · filed 2026-02-24 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | -$65.00K 10-K · filed 2020-03-03 | ||
| 2019-09-30 | -$65.00K 10-Q · filed 2019-11-08 | |||
| 2018-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $182.00K 10-K · filed 2020-03-03 | ||
| 2018-09-30 | $78.00K 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $268.00K 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |